Our product portfolio covers a number of therapy areas not currently listed. Products that fall into this category are detailed below.
menadiol sodium diphosphate
Adverse events (side effects) thought to have been caused by one of our products should be reported to the MHRA via their yellow card scheme and to Alliance’s Pharmacovigilance team. Click here to submit a report
© 2017 Alliance Pharma. PAGE REF: AL/2041/09.15/0.001 Date of preparation: October 2015
You have clicked on a link that will take you to a third-party website that Alliance Pharma is not responsible for. Please read the following disclaimer and click "I agree" to proceed to the third-party website. By clicking to continue you agree that: